Physician profile
Stephanie E Diamond
NPI 1710140785
$10,334.92
in general payments reported to CMS, 2019-2025
37 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $469 · 2021: $1,270 · 2022: $1,797 · 2023: $1,539 · 2024: $2,783 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,363 · Education: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,362.53 |
| Education | $306.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,633.04 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Janssen Biotech, INC. | $1,436.63 | 2019-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $846.23 | 2019-2025 | Winlevi, Ilumya, Absorica Ld |
| Pfizer INC. | $747.85 | 2019-2025 | |
| Leo Pharma INC. | $552.95 | 2019-2025 | Adbry |
| Genzyme Corporation | $491.22 | 2019-2025 | |
| Amgen INC. | $486.71 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $449.56 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $423.36 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Ucb, INC. | $374.58 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $349.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $305.81 | 2019-2025 | Libtayo, Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $265.17 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $229.98 | 2022-2025 | Sotyktu |
| Epi Health, LLC | $223.71 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $219.01 | 2023-2024 | Zoryve |
| Mayne Pharma Commercial LLC | $217.35 | 2019-2025 | |
| Journey Medical Corporation | $135.85 | 2024-2025 | |
| Dermavant Sciences, INC. | $134.99 | 2022-2024 | Vtama |
| Incyte Corporation | $129.63 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.67 | 2023-2025 | Spevigo |
| Almirall LLC | $96.78 | 2019-2022 | |
| Genentech USA, INC. | $75.88 | 2023-2024 | Xolair, Erivedge |
| Vyne Pharmaceuticals INC. | $64.33 | 2020-2021 | |
| Dermira, INC. | $46.38 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $39.51 | 2021 | |
| Organon LLC | $36.10 | 2025 | |
| Janssen Scientific Affairs, LLC | $35.55 | 2021 | |
| Tactile Systems Technology INC | $32.49 | 2024 | Flexitouch Plus, Entre Plus |
| Aclaris Therapeutics, INC. | $29.69 | 2019 | |
| Celgene Corporation | $21.83 | 2019 | |
| Mission Pharmacal Company | $20.40 | 2019 | |
| Encore Dermatology INC. | $19.67 | 2019 | |
| Kyowa Kirin, INC. | $19.38 | 2024 | Poteligeo |
| Verrica Pharmaceuticals INC. | $16.28 | 2023 | Ycanth |
| Sandoz INC. | $13.27 | 2019 | |
| Biofrontera INC. | $10.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.